377 related articles for article (PubMed ID: 28732143)
21. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
[TBL] [Abstract][Full Text] [Related]
22. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
23. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
[TBL] [Abstract][Full Text] [Related]
24. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
[TBL] [Abstract][Full Text] [Related]
25. VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon.
Shan B; Wang JY; Wang X; Fu JJ; Li L; Pan XC; Li JJ; Tang XT
J Med Virol; 2019 May; 91(5):765-774. PubMed ID: 30516836
[TBL] [Abstract][Full Text] [Related]
26. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
27. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
28. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
[TBL] [Abstract][Full Text] [Related]
29. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW
J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898
[TBL] [Abstract][Full Text] [Related]
30. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
31. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.
Holmes JA; Nguyen T; Ratnam D; Heerasing NM; Tehan JV; Bonanzinga S; Dev A; Bell S; Pianko S; Chen R; Visvanathan K; Hammond R; Iser D; Rusli F; Sievert W; Desmond PV; Bowden DS; Thompson AJ
J Gastroenterol Hepatol; 2013 May; 28(5):861-6. PubMed ID: 23301835
[TBL] [Abstract][Full Text] [Related]
32. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
33. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
[TBL] [Abstract][Full Text] [Related]
34. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
Lu J; Zhang S; Liu Y; Du X; Ren S; Zhang H; Ma L; Chen Y; Chen X; Shen C
Liver Int; 2015 Jun; 35(6):1692-9. PubMed ID: 25438657
[TBL] [Abstract][Full Text] [Related]
35. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
[TBL] [Abstract][Full Text] [Related]
36. Peginterferon α in the treatment of chronic hepatitis B.
Tseng TC; Kao JH; Chen DS
Expert Opin Biol Ther; 2014 Jul; 14(7):995-1006. PubMed ID: 24738850
[TBL] [Abstract][Full Text] [Related]
37. Genotype F of hepatitis B: response to interferon.
Venegas M; Poniachik J; Fuster F; Hurtado C; Villanueva RA; Brahm J
Antivir Ther; 2015; 20(4):453-6. PubMed ID: 25321866
[TBL] [Abstract][Full Text] [Related]
38. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population.
Wang H; Wu H; Bao S; Xiang X; Zhao G; Liu K; Li F; Xu Y; An B; Zhou H; Lu J; Xie Q
Infect Genet Evol; 2015 Apr; 31():161-8. PubMed ID: 25640825
[TBL] [Abstract][Full Text] [Related]
39. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B.
Karataylı SC; Bozdayı M; Karataylı E; Öztürk T; Husseini AA; Albayrak R; Özkan M; Kalaylıoğlu Z; Yalçın K; Çınar K; İdilman R; Yurdaydın C
Liver Int; 2015 Mar; 35(3):846-53. PubMed ID: 24840315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
